Humanigen's COVID-19 Candidate Shows 2.5 Fold Increase In Survival Without Ventilation
Humanigen Inc (NASDAQ: HGEN) has announced an analysis of results from its Phase 3 LIVE-AIR study of lenzilumab in hospitalized patients with COVID-19.
Data suggested that Black and African-American patients having a CRP over 150 mg/L may be the highest responders to treatment, with a nearly 9-fold increase in the likelihood of survival without ventilation (SWOV).
As per CDC data, Black and African-American persons are at an almost 3-fold greater risk of hospitalization and 2-fold greater risk of death from COVID-19 infection.
In the overall population with CRP over 150 mg/L, LIVE-AIR Phase 3 results show that patients treated with lenzilumab demonstrated a 2.5-fold increased likelihood of SWOV.
Based on the 520-subject study, the company applied with the FDA seeking Emergency Use Authorization for lenzilumab to treat patients hospitalized with COVID-19.
Humanigen intends to submit data from this analysis for publication in a peer-reviewed journal and present the findings at a medical meeting.
Price Action: HGEN shares are up 1.95% at $16.19 during the premarket session on the last check Wednesday.
See more from Benzinga
CytoSorbents Q2 Earnings Lag Consensus, Higher Costs Weigh On Bottom Line
Cerus Stock Gains As Q2 Earnings Match Expectations, Raises FY21 Sales Guidance
© 2021 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
